Lexette (Halobetasol Propionate) Patent Expiration, LOE Window & CMS Spending

Lexette (Halobetasol Propionate) by Mayne In: FDA Orange Book LOE 2037-05-30, 7 AB generics, $12K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMayne In
FDA Application & PathwayN210566 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2037-05-30
Orange Book Patents (*PED Extensions)3 patents (1 *PED)
Active AB-Rated Generic Competitors7
2024 CMS Total Public Spend$12K
2024 Medicare Part D Spend$0
2024 Medicaid Spend$12K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel